Q-omics provides the consensus-scored TRIM26BP profile across patient tissues and cancer cell-line models. TRIM26BP expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRIM26BP is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, TRIM26BP RNA expression shows 11,969 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, UCEC, and THYM as cancer lineages where TRIM26BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM26BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM26BP survival associations across molecular data types. TRIM26BP RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM26BP RNA expression–survival associations across cancer types. High TRIM26BP expression shows unfavorable associations in UVM, LUAD and BLCA, but favorable associations in UCS, LIHC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for TRIM26BP RNA expression.
This table summarizes TRIM26BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM26BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM26BP shows lower tumor expression in UCEC, READ and THCA and higher tumor expression in COAD and LIHC. The UCEC box plot shows higher TRIM26BP RNA expression in normal versus tumor tissue (log2 FC = −0.240, t-test p = .001).
This table shows molecular features associated with TRIM26BP in patient tissues and cancer cell lines. In patient samples, TRIM26BP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
